[go: up one dir, main page]

MX2015016550A - Antagonistas de imidazolil progesterona. - Google Patents

Antagonistas de imidazolil progesterona.

Info

Publication number
MX2015016550A
MX2015016550A MX2015016550A MX2015016550A MX2015016550A MX 2015016550 A MX2015016550 A MX 2015016550A MX 2015016550 A MX2015016550 A MX 2015016550A MX 2015016550 A MX2015016550 A MX 2015016550A MX 2015016550 A MX2015016550 A MX 2015016550A
Authority
MX
Mexico
Prior art keywords
imidazolyl
compounds
progesterone antagonists
therapy
sign
Prior art date
Application number
MX2015016550A
Other languages
English (en)
Other versions
MX364985B (es
Inventor
Walter Elger
Klaus Nickisch
Santhamma Bindu
Original Assignee
Evestra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evestra Inc filed Critical Evestra Inc
Publication of MX2015016550A publication Critical patent/MX2015016550A/es
Publication of MX364985B publication Critical patent/MX364985B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de imidazolilo que actúan como antiprogestinas puras y métodos de uso de tales antagonistas puros para indicaciones ginecológicas y cáncer de mama.
MX2015016550A 2013-06-05 2014-06-05 Antagonistas de imidazolil progesterona. MX364985B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/910,273 US9096641B2 (en) 2013-06-05 2013-06-05 Imidazolyl progesterone antagonists
PCT/US2014/041002 WO2014197653A2 (en) 2013-06-05 2014-06-05 Imidazolyl progesterone antagonists

Publications (2)

Publication Number Publication Date
MX2015016550A true MX2015016550A (es) 2016-12-12
MX364985B MX364985B (es) 2019-05-09

Family

ID=52005991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016550A MX364985B (es) 2013-06-05 2014-06-05 Antagonistas de imidazolil progesterona.

Country Status (14)

Country Link
US (1) US9096641B2 (es)
EP (1) EP2999475B1 (es)
JP (1) JP2016520649A (es)
KR (1) KR20160051693A (es)
CN (1) CN105530943B (es)
AU (1) AU2014274930B2 (es)
BR (1) BR112015030308A2 (es)
CA (1) CA2917031C (es)
ES (1) ES2683446T3 (es)
HU (1) HUE041548T2 (es)
MX (1) MX364985B (es)
PL (1) PL2999475T3 (es)
RU (1) RU2679445C2 (es)
WO (1) WO2014197653A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081383A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
EP3394078A4 (en) * 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
EP3394079A4 (en) 2015-12-23 2019-08-21 Oric Pharmaceuticals, Inc. INHIBITORS OF GLUCOCORTICOIDREZEPTORS
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP2019513706A (ja) * 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド オナプリストン代謝物質組成物及び方法
CN111690031B (zh) * 2016-10-07 2021-06-01 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
EP0289073B1 (en) 1987-04-24 1991-11-27 Akzo N.V. Novel 11-aryloestrane and 11-arylpregnane derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
FR2688004A1 (fr) 1992-02-27 1993-09-03 Roussel Uclaf Nouveaux sterouides comportant en position 17 un radical methylene lactone, leur procede et des intermediaires de preparation, leur application comme medicaments.
CA2100514C (en) 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
IL119649A (en) 1995-11-30 2002-03-10 Akzo Nobel Nv Preparation of Cyclic Kills of History - 3 keto- (5) 10, (-9) 11 steroidadians
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
DE60021422T2 (de) 1999-12-29 2006-05-24 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Verfahren zur Herstellung von 17α-acetoxy-11β-[4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dion, für das Verfahren nützliche Zwischenprodukte und Verfahren zur Herstellung derartiger Zwischenprodukte
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US8673968B2 (en) 2009-04-06 2014-03-18 Evestra, Inc. Progesterone antagonists
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists

Also Published As

Publication number Publication date
ES2683446T3 (es) 2018-09-26
AU2014274930B2 (en) 2018-11-08
MX364985B (es) 2019-05-09
RU2015156415A3 (es) 2018-03-27
PL2999475T3 (pl) 2019-08-30
EP2999475A2 (en) 2016-03-30
US20140364600A1 (en) 2014-12-11
BR112015030308A2 (pt) 2017-07-25
AU2014274930A1 (en) 2016-01-28
CA2917031C (en) 2021-12-07
RU2015156415A (ru) 2017-07-14
WO2014197653A3 (en) 2015-04-30
KR20160051693A (ko) 2016-05-11
CA2917031A1 (en) 2014-12-11
HUE041548T2 (hu) 2019-05-28
JP2016520649A (ja) 2016-07-14
WO2014197653A2 (en) 2014-12-11
EP2999475B1 (en) 2018-07-25
CN105530943B (zh) 2018-11-16
CN105530943A (zh) 2016-04-27
EP2999475A4 (en) 2017-02-15
RU2679445C2 (ru) 2019-02-11
US9096641B2 (en) 2015-08-04

Similar Documents

Publication Publication Date Title
MX364985B (es) Antagonistas de imidazolil progesterona.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
SA518391170B1 (ar) مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأمراض، طب الأعصاب وعلم المناعة
GEP20217317B (en) Combination therapy for the treatment of cancer
PH12017502270A1 (en) Combination therapy for the treatment of cancer
NZ749218A (en) Androgen receptor modulator and uses thereof
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX360774B (es) Antagonistas de progesterona.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
IN2013MU03118A (es)
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
IL255168A0 (en) Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.
IN2013MU02732A (es)

Legal Events

Date Code Title Description
FG Grant or registration